Table 4.
Change in Metabolic Syndrome Components and Related Markers of Insulin Resistance From Prepregnancy (Baseline) to Diagnosis of Metabolic Syndrome or Final Coronary Artery Risk Development in Young Adults Study Examination, According to Preterm Birth Statusa
| Term (N=910) | Preterm (N=295) | p-valueb | |
|---|---|---|---|
| Change in Waist Circumference (cm) | 15.5 ± 11.0 | 16.7 ± 10.4 | 0.093 |
| Change in Triglycerides (mg/dl) | 33.4 ± 61.8 | 35.2 ± 78.1 | 0.672 |
| Change in HDL Cholesterol (mg/dl) | 5.1 ± 16.2 | 2.4 ± 14.6 | 0.013 |
| Change in Systolic Blood Pressure (mmHg) | 8.2 ± 15.3 | 11.2 ± 15.8 | 0.003 |
| Change in Diastolic Blood Pressure (mmHg) | 6.3 ± 12.4 | 8.9 ± 12.2 | 0.002 |
| Added Blood Pressure Meds, % | 111 (12.2%) | 52 (17.6%) | 0.017 |
| Change in Glucose (mg/dl) | 12.6 ± 16.8 | 14.0 ± 19.2 | 0.255 |
| Added Diabetes Meds, % | 17 (1.9%) | 6 (2.0%) | 0.858 |
| Weight gain (kg) | 15.8 ± 14.0 | 18.2 ± 13.4 | 0.009 |
| Incident pre-diabetes statusc | 121 (13.3%) | 53 (18.0%) | 0.047 |
| Change in HOMA-IRd | 3.3 ± 4.4 | 4.1 ± 4.3 | 0.180 |
a
Continuous variables displayed as mean ± SD; categorical variables shown as n (%); all changes are positive
b
P-value from t-test (continuous) or chi squared (categorical)
c
Pre-diabetes status (fasting glucose between 100–125 mg/dl) achieved between baseline and metabolic syndrome diagnosis or final visit
d
HOMA-IR, homeostatis model assessment measure of insulin resistance